Amgen (NASDAQ:AMGN) Price Target Raised to $303.00 at Mizuho

Amgen (NASDAQ:AMGN) had its price objective hoisted by investment analysts at Mizuho from $295.00 to $303.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the medical research company’s stock. Mizuho’s price target indicates a potential downside of 13.56% from the company’s current price.

Several other equities analysts have also weighed in on AMGN. Jefferies Financial Group began coverage on shares of Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price objective on the stock. Piper Sandler restated an “overweight” rating on shares of Amgen in a research note on Friday. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a research note on Friday, June 5th. Truist Financial upped their price target on shares of Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research note on Friday, May 1st. Finally, Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Sunday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $354.42.

Amgen Stock Performance

NASDAQ AMGN opened at $350.53 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The firm’s fifty day moving average price is $341.03 and its two-hundred day moving average price is $345.86. Amgen has a 1 year low of $267.83 and a 1 year high of $391.29. The firm has a market capitalization of $189.18 billion, a P/E ratio of 24.39, a price-to-earnings-growth ratio of 3.56 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts anticipate that Amgen will post 22.38 EPS for the current year.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.85% of the stock is owned by insiders.

Institutional Investors Weigh In On Amgen

Large investors have recently bought and sold shares of the company. Anfield Capital Management LLC grew its stake in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares in the last quarter. Dogwood Wealth Management LLC grew its stake in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares in the last quarter. Board of the Pension Protection Fund acquired a new stake in Amgen during the fourth quarter worth about $26,000. Tower View Wealth Management LLC grew its stake in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after buying an additional 63 shares in the last quarter. Finally, Manning & Napier Advisors LLC grew its stake in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.